CurrentUnitedHealthcarePolicy 2026T0498CC

Prolotherapy and Platelet Rich Plasma Therapies

UnitedHealthcare Commercial and Individual Exchange medical policy defining coverage stance, rationale, and referenced procedure/diagnosis codes for prolotherapy and platelet-rich plasma therapies. This part (1 of 6) includes policy identification, coverage rationale (overall determination of medical necessity), description of services, summary of evidence across multiple indications (low back pain, osteoarthritis, knee, etc.), and applicable procedure and HCPCS/CPT codes for PRP and prolotherapy.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies

Policy CodePolicy 2026T0498CC

Change TypeTemplate Update

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument indication, prior conservative therapies, PRP/prolotherapy preparation and administration details, and informed consent noting limited and heterogeneous evidence when submitting for coverage or medical review.

SourceLink

POLICY UPDATE CHANGES

Template Update: Created shared policy version to support application to Oxford plan membership and updated Supporting Information, Clinical Evidence and References sections.

2Therapies listed as not medically necessary

5Code entries referenced in Part 1

multipleEvidence citations in this part

present

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Heterogeneity across studies

fewSerious adverse events reported

Coverage Summary

Policy Number: 2026T0498CC; Effective Date: January 1, 2026. Scope: UnitedHealthcare Commercial and Individual Exchange medical policy part addressing prolotherapy and platelet-rich plasma (PRP) therapies, referenced CPT/HCPCS/other codes, and coverage rationale for these therapies under the plan. Coverage stance: Not covered / unproven / not medically necessary for any condition or indication (therapies listed: Prolotherapy and Platelet-rich plasma).

Overview: This policy part addresses injection-based regenerative therapies including prolotherapy (injections of irritant solutions such as hypertonic dextrose, saline, local anesthetic) and platelet-rich plasma (autologous concentrated platelets/growth factors). Based on the policy's review, these therapies are considered unproven and not medically necessary for any condition or indication due to insufficient and heterogeneous evidence and lack of standardized preparations or protocols. The policy lists relevant procedure and HCPCS/CPT codes (e.g., 0232T, G0460, G0465, M0076, P9020) for reference only and notes that code listing does not imply coverage.

Key facts (brief)

Therapies listed as not medically necessary2 (Prolotherapy; Platelet‑rich plasma)

Code entries referenced5 (0232T, G0460, G0465, M0076, P9020)

Evidence qualityLow to very low for most indications

Short‑term benefitsSome short‑term benefit reported in select conditions

Serious adverse eventsFew reported

Medical-Necessity Determinations

Coverage Rationale - Medical Necessity Determination

Due to insufficient evidence of efficacy, the following are unproven and not medically necessary for any condition or indication:

ALL of the following

Prolotherapy
Listed as unproven and not medically necessary for any condition or indication.
Platelet-rich plasma
Listed as unproven and not medically necessary for any condition or indication.

Evidence-based conclusions (narrative)

Coverage interpretation is guided by the quality and consistency of evidence; summarized conclusions from multiple systematic reviews, RCTs, and observational studies are provided:

Evidence Synthesis and Applicability

Background: Prolotherapy is described as injection of substances (for example, hypertonic dextrose, saline, sarapin, procaine, or lidocaine) administered intra- or periarticularly to stimulate a local inflammatory/healing response intended to strengthen and repair ligaments, tendons, or joint structures. PRP is an autologous blood preparation with a high platelet concentration intended to deliver concentrated platelet-derived growth factors and cytokines to promote regeneration and tissue repair.

Heterogeneity of PRP: PRP preparations are not standardized across studies and exhibit wide variability in platelet concentration, leukocyte content (leukocyte-rich vs leukocyte-poor), activation methods, volumes, and application techniques; the policy explicitly notes that it is unclear how these compositional differences affect clinical outcomes.

Evidence base limits: The overall evidence for both prolotherapy and PRP across indications is limited by small, heterogeneous, often low- to moderate-quality trials, inconsistent protocols (preparation, dosing, injection technique, number and timing of injections), short follow-up durations, variable comparators, and inconsistent adverse-event reporting—factors that prevent firm conclusions about clinical efficacy or long-term safety.

Evidence synthesis and applicability

Summarized findings and limitations from randomized trials, systematic reviews, and technology assessments:

Indication-specific evidence summaries

Low back pain:

Definitions

Term	Definition
Prolotherapy	Injection of any substance (e.g., dextrose, saline, sarapin, procaine or lidocaine) to promote growth of normal cells, tissues, or organs by stimulating a healing response; injection therapy typically using hypertonic dextrose solutions administered intraarticularly or periarticularly to promote healing or reduce pain. (Also described as proliferative therapy and includes growth factor injection, growth factor stimulation, and inflammatory prolotherapy.)
Platelet-rich plasma (PRP)	Autologous blood preparation with a high platelet concentration and concentrated platelet-derived growth factors and other cytokines intended to stimulate regeneration and tissue repair; PRP preparations vary (leukocyte-rich vs leukocyte-poor) and are not standardized.
DPT	Dextrose Prolotherapy (hypertonic dextrose injection).
PRP	Platelet-Rich Plasma (see definition above: autologous blood product concentrated for platelets; preparations and leukocyte content vary across studies).
HA	Hyaluronic Acid.
KOA	Knee Osteoarthritis.
AOFAS	American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score.
VISA-P	Victorian Institute of Sport Assessment-Patella score.
Prolotherapy (DPT)	Injection therapy typically using hypertonic dextrose solutions, administered intraarticularly or periarticularly to promote healing or reduce pain (described in policy as Prolotherapy and DPT).
PRP (general)	Platelet-rich plasma — autologous blood product concentrated for platelets used in injections or topical applications to promote healing; preparations and leukocyte content vary across studies and lack standardization.
Prolotherapy (procedure description)	Orthopedic procedure that stimulates the body's healing processes to strengthen and repair injured joints and connective tissue by directed injections that provoke a mild inflammatory response to encourage new ligament or tendon fiber growth; newer formulas may include PRP or autologous stem cell sources.
PRP (safety/standardization note)	PRP preparations are heterogeneous and not standardized; evidence fails to conclusively substantiate clinical efficacy and long-term safety, and variations in composition may affect outcomes.

Coding

CPT / HCPCS / Other codes referencedmixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy.
P9020	Platelet rich plasma, each unit

Provider Actions & Administrative Implications

Prior Authorization

Prior Authorization May Be Required

Given mixed and often low-quality evidence for prolotherapy and platelet-rich plasma (PRP), payer may require prior authorization to ensure appropriate use and documentation of medical necessity prior to payment determination.

Denial Risk

Denial Risk for Inadequate Documentation or Unsupported Indications

Claims for PRP or prolotherapy may be denied or subject to medical review if documentation does not demonstrate that the treatment meets plan-specific medically necessary criteria or if evidence limitations are not addressed in the record.

Documentation Required

Documentation Requirements and Evidence Rationale

Evidence Details and Citations (Selected)

Evidence highlights: randomized trials and systematic reviews provide mixed results across indications. For knee osteoarthritis (KOA), some meta-analyses and RCTs report short- to mid-term symptom benefit for PRP versus hyaluronic acid or placebo, but large, high-quality trials show inconsistent results; for example, the Bennell et al. (2021) randomized trial (n=288) found no difference between leukocyte-poor PRP and saline placebo for pain or medial tibial cartilage volume at 12 months, while other meta-analyses/meta-reviews report PRP superiority at some time points but note low-quality and heterogeneous evidence.

Selected study callouts: a small RCT (Rahimzadeh et al. 2018, n=42) reported WOMAC improvements with both PRP and dextrose prolotherapy up to 6 months; a large lateral epicondylosis RCT (Lhee et al. 2025) reported greater DASH improvements with PRP and prolotherapy versus physiotherapy at 24 months in that single trial; intradiscal and other low back pain RCTs/meta-analyses show mixed short-term benefits (examples: Tuakli-Wosornu 2016 intradiscal RCT with early benefit sustained through 1 year; Singh 2023 small RCT for IVDP reported greater pain reduction with PRP at 6 months).

Safety and harms examples: safety data generally report few serious adverse events in the short term but inconsistent reporting overall; however, a focused meta-analysis for foot and ankle pathologies (Fucaloro et al. 2025) identified a higher overall complication rate with PRP (41.1% vs 33.7%), including increased treatment-site pain (PRP 15.1% vs comparator 10.2%) and an estimated NNH = 13 for any complication in that pooled analysis. Technology assessments for wounds (Hayes, ECRI) indicate low-to-moderate evidence that PRP may improve diabetic foot ulcer healing (Hayes C rating; ECRI: evidence somewhat favorable) but recommend against routine use because of heterogeneity in protocols and uncertain generalizability; evidence for venous leg ulcers is inconclusive.

Overall summary: Across musculoskeletal, spinal, soft tissue, surgical adjunct, and wound indications, the body of evidence is heterogeneous with many small single-center RCTs and systematic reviews showing inconsistent or limited-duration benefits; professional society guidance is mixed and several assessments (Hayes, ECRI) emphasize insufficient, low-quality evidence and lack of standardized PRP/prolotherapy protocols—supporting the policy determination that these therapies remain unproven and not medically necessary for any indication.

Revision History

2026-01-01archival/revisionLatest

Archived previous policy version 2025T0498BB; Template Update: Created shared policy version to support application to Oxford plan membership and updated Supporting Information, Clinical Evidence and References sections.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies

Policy CodePolicy 2026T0498CC

Change TypeTemplate Update

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

PRP preparations are heterogeneous and lack standardization; evidence quality is variable and often low-to-moderate.

For knee osteoarthritis (KOA), some meta-analyses and RCTs show short- to mid-term pain/function benefit for PRP versus placebo or hyaluronic acid, with inconsistent results across high-quality trials (several trials show no difference at 12 months).

For temporomandibular joint disorders, small RCTs and observational studies suggest prolotherapy may reduce pain and dislocation episodes, but studies are limited by small sample sizes, bias concerns, heterogeneity of interventions, and short follow-up.

For lower limb tendinopathies (Achilles, patellar, ankle), evidence for prolotherapy or PRP is mixed; some systematic reviews/meta-analyses and small controlled trials report pain/function improvements but overall conclusions limited by heterogeneity and low-quality studies.

For hip osteoarthritis, evidence is limited and does not consistently demonstrate benefit beyond placebo for PRP; small low-quality RCTs and reviews indicate potential but unproven benefit.

For soft tissue injuries, meniscal repair augmentation, ACL reconstruction, and surgical adjuncts, systematic reviews report inconsistent or insufficient evidence to support routine PRP use; some subanalyses show potential benefits in select contexts but not consistently replicated.

Safety data generally report few serious adverse events short-term, but long-term safety and standardized preparation/administration data are lacking.

Several small RCTs and prospective studies report mixed results for intradiscal, epidural, facet joint, sacroiliac, and ligament injections of PRP or prolotherapy; some trials show short-term pain/function improvements while others show minimal or inconsistent benefit; common limitations include small sample sizes and short follow-up.

Wounds: Hayes and ECRI assessments indicate PRP may improve diabetic foot ulcer healing (Hayes C rating; ECRI: evidence somewhat favorable) but routine use is not recommended due to heterogeneity and uncertain protocols; evidence for venous leg ulcers is inconclusive.

Musculoskeletal (OA, rotator cuff, tendinopathy): Professional society guidance and systematic reviews show mixed findings: some meta-analyses and RCTs report short-term benefits for PRP/prolotherapy in KOA and some tendinopathies, but results are inconsistent and evidence quality is often low; recommendations vary across AAOS, ACR, AAHKS and others.

Common limitations across evidence

Heterogeneity in PRP preparation protocols, platelet concentrations, application methods, and dosing/frequency.
Small, single-center trials with short follow-up durations limiting generalizability.
Inconsistent reporting of adverse events and inconsistent outcome measures across studies.

Evidence summary (brief)

Overall evidence qualityInsufficient; studies limited, heterogeneous, often low or very low quality

Randomized trials / systematic reviews citedMultiple RCTs and systematic reviews (examples include Bennell et al. RCT, Filardo meta-analysis, Hayes and ECRI assessments)

Example note 1KOA: Bennell RCT (n=288) — no difference between PRP and saline placebo at 12 months

Example note 2Wounds: Hayes and ECRI assessments — PRP may improve DFU healing (Hayes C; ECRI: somewhat favorable) but routine use not recommended

Example note 3PRP preparations not standardized; trials small, short follow-up, inconsistent outcomes and AE reporting

Maintain comprehensive clinical documentation supporting the use of PRP or prolotherapy. Include the indication, objective measures of severity, prior conservative therapies and their duration/outcomes, details of PRP preparation and composition, injection technique and anatomic targets, informed consent discussing experimental/ unproven status, and the evidence-based rationale for use when applicable. Also confirm that the indication is consistent with current evidence and guidelines and note that many indications remain potentially noncovered given insufficient evidence.

Indication and clinical rationale, including objective severity measures (e.g., validated pain or function scores).
Documentation of prior conservative therapies (type, duration, response) and why alternatives were insufficient.
Detailed PRP preparation and composition (platelet concentration, leukocyte content, device used) and number/volume of injections.
Injection technique and targeted anatomy (image guidance, provider specialty).
Informed consent noting experimental/ investigational or unproven status for many indications.
Evidence-based rationale or supporting literature when available; be prepared to justify use against current guideline positions.
Verify member-specific benefit plan for coverage details and limits.
For Medicare Advantage members, check applicable Medicare guidance and coverage policies.

Billing Rule

Billing and Coding Note

Listing a code in this policy does not imply coverage. Providers should verify member-specific benefits for coverage and reimbursement. Historically, policy application has extended to Oxford membership where applicable; check the member's plan documents for any Oxford-specific provisions.

Code inclusion is for reference only and is not a guarantee of coverage.
Confirm member-specific benefit plan before billing.
Policy historically applied to Oxford membership in applicable markets — verify current plan applicability.